.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Cerilliant
Citi
Dow
Covington
US Army
Cantor Fitzgerald
McKesson
Harvard Business School

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091226

« Back to Dashboard
NDA 091226 describes ATORVASTATIN CALCIUM, which is a drug marketed by Teva Pharms Usa, Sciegen Pharms Inc, Kremers Urban Pharms, Mylan Pharms Inc, Invagen Pharms, Apotex Inc, Dr Reddys Labs Ltd, Teva Pharms, Sandoz Inc, and Sun Pharm Inds Ltd, and is included in eleven NDAs. It is available from forty-nine suppliers. Additional details are available on the ATORVASTATIN CALCIUM profile page.

The generic ingredient in ATORVASTATIN CALCIUM is atorvastatin calcium. There are sixty-one drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

Summary for 091226

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 091226

Medical Subject Heading (MeSH) Categories for 091226

Suppliers and Packaging for NDA: 091226

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL 091226 ANDA Mylan Pharmaceuticals Inc. 0378-3950 0378-3950-05 500 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-3950-05)
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL 091226 ANDA Mylan Pharmaceuticals Inc. 0378-3950 0378-3950-07 500 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-3950-07)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:May 29, 2012TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:May 29, 2012TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 40MG BASE
Approval Date:May 29, 2012TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
McKesson
Federal Trade Commission
UBS
Covington
Chinese Patent Office
Chubb
Moodys
Citi
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot